A federal law requires pharmaceutical manufacturers to sell discounted medicines to specific hospitals and clinics. That discount mechanism, the foundation of the 340B Drug Pricing Program, is now being reshaped. The Trump administration revised the terms of a pilot effort within the program, replacing automatic upfront price cuts with a rebate model where savings arrive after the purchase, not at the point of sale. The change takes effect January 1, 2027, and it has drawn sharp objections from hospitals.
What the current program does
The 340B Drug Pricing Program is a federal requirement for pharmaceutical manufacturers to provide covered outpatient drugs at reduced prices to certain health care providers. These providers include specific hospitals and clinics. The discount is currently embedded in the purchase price: the hospital or clinic pays less at the moment it buys the drug. The program is administered by the Health Resources and Services Administration, a federal agency.
How the pilot changes the payment structure
The revised pilot replaces that immediate price reduction with a rebate. In plain terms, a rebate is a payment a company makes to a buyer after a transaction closes, not before it. Under the pilot, pharmaceutical companies would provide these rebates on a "timely" basis, according to the administration. When savings actually reach covered providers, and by how much, are details the announcement does not specify.
The pilot covers specific drugs and companies that are part of the first two rounds of the Medicare Drug Price Negotiation Program. That program is the separate federal process through which the government negotiates lower prices directly with manufacturers.
What the agency says and what hospitals hear
Tom Engels, who leads the Health Resources and Services Administration, said the revised pilot will modernize oversight by improving visibility into 340B transactions and help preserve the program's long-term sustainability for the patients and communities it was created to serve.
For hospitals, the core concern is timing. A discount built into the purchase price is a certainty. A rebate delivered after the fact is a promise. Hospitals that depend on the program have pushed back sharply on the revision. The pilot is scheduled to begin on January 1, 2027.